The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

voglibose     5-(1,3-dihydroxypropan-2- ylamino)-1...

Synonyms: CCRIS 4540, AG-J-09686, AC1L1KVZ, KB-62271, LS-84058, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of voglibose


High impact information on voglibose


Chemical compound and disease context of voglibose


Biological context of voglibose

  • CONCLUSION: Improvement of glycemic control through voglibose therapy inhibited cardiac remodeling by decreasing myocardial oxidative stress in mice with cardiac pressure overload [3].
  • Echocardiographic and invasive hemodynamic examination showed improvement of left ventricular function in voglibose-treated mice [3].
  • Food intake of fatty rats treated with AO-128 was decreased throughout the experiment [4].
  • The maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of plasma IRI after meals decreased significantly with all treatments except voglibose 0.3 mg compared with placebo [16].
  • Pioglitazone significantly decreased systolic and diastolic blood pressure levels at 12 weeks, but voglibose had no effect [17].

Anatomical context of voglibose

  • A new disaccharidase inhibitor, AO-128, showed 190-3900-fold more potent inhibition of purified rat small intestine sucrase-isomaltase (S-1) complex and 23-33-fold more potent inhibition of semipurified porcine small intestine disaccharidases than acarbose [1].
  • In addition, AO-128 decreased body weight gain, food efficiency, epididymal adipose tissue weight, carcass weight, and body fat deposition [4].
  • Metabolic improvements associated with a reduction of abdominal visceral fat caused by a new alpha-glucosidase inhibitor, AO-128, in Zucker fatty rats [18].
  • Administration of AO-128 (50 p.p.m./day), a new alpha-glucosidase inhibitor, caused a substantial reduction of mesenteric fat weight accompanied by a marked decrease in fat cell volume in Zucker fatty rats [18].
  • The present study was designed to determine the possible significance of a therapeutic dose (0.2 mg) of AO-128 on carbohydrate absorption by measuring the breath hydrogen concentration, which is an index of the amount of unabsorbed carbohydrate in the large intestine [19].

Associations of voglibose with other chemical compounds


Gene context of voglibose


Analytical, diagnostic and therapeutic context of voglibose

  • Insulin sensitivity (KITT) was improved to a statistically significant level in both the patients treated with voglibose and the patients in the control group [9].
  • A statistically significant increase in AUCinsulin occurred after treatment with voglibose (2,223.5 +/- 390.6 to 1,546.7 +/- 303.4 pmol.l-1.h, P < 0.05), but no change occurred in the control group (2,364.5 +/- 315.4 to 2,464.2 +/- 269.3 pmol.l-1.h, P = 0.60) [9].
  • Urinary CPR excretion decreased by 30.6% and 41.7%, respectively, in subjects who received acarbose 50 mg or 100 mg compared with the previous day when no drug was given, whereas the urinary CPR excretion did not decrease significantly with voglibose [16].
  • Oral administration of voglibose prolonged the duration of normoglycaemia and reduced the incidence of hypoglycaemia attacks [24].
  • Analysis of the diurnal metabolic profiles revealed a significant reduction of postprandial hyperglycemia and hyperlipidemia in the voglibose group relative to the control group (P<.05), despite the similar improvement in body mass index and hemoglobin A(1c) in both groups [22].


  1. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Matsuo, T., Odaka, H., Ikeda, H. Am. J. Clin. Nutr. (1992) [Pubmed]
  2. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Chen, X., Zheng, Y., Shen, Y. Current medicinal chemistry. (2006) [Pubmed]
  3. Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Liao, Y., Takashima, S., Zhao, H., Asano, Y., Shintani, Y., Minamino, T., Kim, J., Fujita, M., Hori, M., Kitakaze, M. Cardiovasc. Res. (2006) [Pubmed]
  4. AO-128, alpha-glucosidase inhibitor: antiobesity and antidiabetic actions in genetically obese-diabetic rats, Wistar fatty. Ikeda, H., Odaka, H. Obes. Res. (1995) [Pubmed]
  5. Repeated episodes of paralytic ileus in an elderly diabetic patient treated with voglibose. Oba, K., Suzuki, K., Ouchi, M., Matsumura, N., Suzuki, T., Nakano, H. Journal of the American Geriatrics Society. (2006) [Pubmed]
  6. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Ihara, Y., Toyokuni, S., Uchida, K., Odaka, H., Tanaka, T., Ikeda, H., Hiai, H., Seino, Y., Yamada, Y. Diabetes (1999) [Pubmed]
  7. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Takami, K., Takeda, N., Nakashima, K., Takami, R., Hayashi, M., Ozeki, S., Yamada, A., Kokubo, Y., Sato, M., Kawachi, S., Sasaki, A., Yasuda, K. Diabetes Care (2002) [Pubmed]
  8. The efficacy of voglibose on glycemic excursions in non-insulin-treated NIDDM patients. Yoshioka, K., Yokoo, S., Yoshida, T. Diabetes Care (1998) [Pubmed]
  9. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Matsumoto, K., Yano, M., Miyake, S., Ueki, Y., Yamaguchi, Y., Akazawa, S., Tominaga, Y. Diabetes Care (1998) [Pubmed]
  10. Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients. Kawagishi, T., Nishizawa, Y., Taniwaki, H., Tanaka, S., Okuno, Y., Inaba, M., Ishimura, E., Emoto, M., Morii, H. Diabetes Care (1997) [Pubmed]
  11. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Vichayanrat, A., Ploybutr, S., Tunlakit, M., Watanakejorn, P. Diabetes Res. Clin. Pract. (2002) [Pubmed]
  12. Voglibose inhibits postprandial hypotension in neurologic disorders and elderly people. Maruta, T., Komai, K., Takamori, M., Yamada, M. Neurology (2006) [Pubmed]
  13. Efficacy and Adverse Effects of Nateglinide in Early Type 2 Diabetes. Comparison with Voglibose in a Cross-over Study. Kurebayashi, S., Watada, H., Tanaka, Y., Kawasumi, M., Kawamori, R., Hirose, T. Endocr. J. (2006) [Pubmed]
  14. Pneumatosis cystoides intestinalis after alpha-glucosidase inhibitor treatment in a patient with interstitial pneumonitis. Hisamoto, A., Mizushima, T., Sato, K., Haruta, Y., Tanimoto, Y., Tanimoto, M., Matsuo, K. Intern. Med. (2006) [Pubmed]
  15. A Rare Case of Adult-onset Nesidioblastosis Treated Successfully with Diazoxide. Arao, T., Okada, Y., Hirose, A., Tanaka, Y. Endocr. J. (2006) [Pubmed]
  16. Comparison of the effects of acarbose and voglibose in healthy subjects. Kageyama, S., Nakamichi, N., Sekino, H., Nakano, S. Clinical therapeutics. (1997) [Pubmed]
  17. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Shimizu, H., Oh-I, S., Tsuchiya, T., Ohtani, K.I., Okada, S., Mori, M. Diabet. Med. (2006) [Pubmed]
  18. Metabolic improvements associated with a reduction of abdominal visceral fat caused by a new alpha-glucosidase inhibitor, AO-128, in Zucker fatty rats. Kobatake, T., Matsuzawa, Y., Tokunaga, K., Fujioka, S., Kawamoto, T., Keno, Y., Inui, Y., Odaka, H., Matsuo, T., Tarui, S. International journal of obesity. (1989) [Pubmed]
  19. An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. Goto, Y., Yamada, K., Ohyama, T., Matsuo, T., Odaka, H., Ikeda, H. Diabetes Res. Clin. Pract. (1995) [Pubmed]
  20. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Fuder, H., Kleist, P., Birkel, M., Ehrlich, A., Emeklibas, S., Maslak, W., Stridde, E., Wetzelsberger, N., Wieckhorst, G., Lücker, P.W. Eur. J. Clin. Pharmacol. (1997) [Pubmed]
  21. Inhibitory effect of voglibose and gymnemic acid on maltose absorption in vivo. Luo, H., Imoto, T., Hiji, Y. World J. Gastroenterol. (2001) [Pubmed]
  22. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Satoh, N., Shimatsu, A., Yamada, K., Aizawa-Abe, M., Suganami, T., Kuzuya, H., Ogawa, Y. Metab. Clin. Exp. (2006) [Pubmed]
  23. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Göke, B., Fuder, H., Wieckhorst, G., Theiss, U., Stridde, E., Littke, T., Kleist, P., Arnold, R., Lücker, P.W. Digestion (1995) [Pubmed]
  24. Prevention of hypoglycaemia in a patient with type Ib glycogen storage disease by an amylase (alpha-glucosidase) inhibitor. Ihara, K., Kuromaru, R., Ryu, A., Fukushige, J., Hara, T. Acta Paediatr. (1998) [Pubmed]
WikiGenes - Universities